Sunshine Biopharma, Inc. (the "Company") was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006 in the State of Colorado. Until October 2009, the Company was operating as a business consultancy firm. Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. was holding an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a. Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the development of the licensed Adva-27a anticancer drug. In July 2014, the Company formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (Sunshine Canada) for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs for treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia). On January 1, 2018, the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (Atlas), a Canadian privately held analytical chemistry company. The purchase price for the shares was Eight Hundred Forty Eight Thousand Dollars $848,000 Canadian ($676,748 US). The purchase price included a cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 1,000,000 shares of the Companys Common Stock valued at $238,000 or $0.238 per share, and a promissory note in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum. Effective April 1, 2019, the Company re-assigned all of its stock in Atlas back to the original owner in exchange for the Atlas related debt. The loss on the disposition was $580,125. In March 2018, the Company formed NOX Pharmaceuticals, Inc., a wholly owned Colorado corporation and assigned all of the Companys interest in the Adva27a anticancer drug to that company. NOX Pharmaceuticals Inc.s mission is to research, develop and commercialize proprietary drugs including Adva-27a. On December 17, 2018, the Company launched its first over-the-counter product, Essential 9 tm , a dietary supplement comprised of the nine essential amino acids that the human body cannot synthesize. Essential 9 tm has been authorized for marketing by Health Canada under NPN 80089663. Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its $0.001 par value Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the Reverse Stock Split). The number of authorized Common Shares was established at 3,000,000,000 post-split. The Company's financial statements reflect the Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and its subsidiaries (Sunshine Biopharma Canada Inc. and NOX Pharmaceuticals Inc.) herein collectively referred to as the "Company". During the last nine month period the Company has continued to raise money through the issuance of convertible debt. The Companys activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Companys generics business and proprietary drug development program. Basis of Presentation of Unaudited Financial Information The unaudited financial statements of the Company for the three and nine month periods ended September 30, 2019 and 2018 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of September 30, 2019 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2018 included in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on April 12, 2019. These financial statements should be read in conjunction with that report. Recently Issued Accounting Pronouncements Recently issued amendments by the FASB are effective for fiscal years beginning after December 15, 2018, and should be applied prospectively on or after the adoption date. Early adoption is permitted, including adoption in an interim period. The Company does not expect these amendments to have a material impact on its financial statements. In February 2016, the FASB issued ASU 2016-02, Leases, effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted as of the beginning of an interim or annual period. This update requires organizations to recognize lease assets and lease liabilities on the balance sheet with lease terms of more than 12 months and also disclose certain qualitative and quantitative information about leasing arrangements. The Company adopted this pronouncement on January 1, 2019. Discontinued Operations Effective April 1, 2019, the Company disposed of its Atlas Pharma Inc. subsidiary. As a consequence of the sale, the operating results and the assets and liabilities of the discontinued operations, which formerly comprised the lab testing operations, are presented separately in the Company's financial statements. Summarized financial information for the discontinued business is shown below. Prior period balances have been reclassified to present the operations of the lab testing business as a discontinued operation. Discontinued Operations Income Statement: Unaudited Unaudited Unaudited Unaudited 3 Month Ended 3 Month Ended 9 Month Ended 9 Month Ended September 30, September 30, September 30, September 30, 2019 2018 2019 2018 Revenues $ - $ 136,939 $ 119,522 $ 335,357 Cost of revenues - 100,219 81,920 285,210 Gross profit - 36,720 37,602 50,147 General&amp; Administrative Expenses - 27,649 36,196 46,970 Gain (Loss) from operations - 9,071 1,406 3,177 Other income (expense)  Interest - (3,793 ) (3,518 ) (12,024 ) Net Income (Loss) from operations - 5,278 (2,112 ) (8,847 ) Loss on Disposal - - (580,125 ) - Total Net Income (Loss) from Discontinued Operations - 5,278 (582,237 ) (8,847 ) The individual assets and liabilities of the discontinued lab testing business are in the captions "Assets of Discontinued Operation" and "Liabilities of Discontinued Operation" in the Consolidated Balance Sheet. The carrying amounts of the major classes of assets and liabilities included part of the discontinued business are presented in the following table: Discontinued Operations Balance Sheets: ASSETS Unaudited September 30, 2019 Unaudited December 31, 2018 Current Assets: Cash and cash equivalents $ - $ 4,682 Accounts receivable - 94,955 Total Current Assets - 99,637 Equipment (net of $ 0 and $34,959 depreciation) - 224,238 Goodwill - 665,697 TOTAL ASSETS $ - $ 989,572 LIABILITIES Current Liabilities: Notes payable - 4,657 Notes payable - related party - 18,230 Related party advances - 10,248 Accounts payable &amp; accrued expenses - 70,597 Total Current Liabilities - 103,732 TOTAL LIABILITIES $ - $ 103,732 Discontinued Operations Cash Flows: Cash flows used in discontinued operations for the nine months ended September 30, 2019 and 2018 were $8,510 and $17,342, respectively. There were no cash flows used in or provided by investing activities during those periods.